BIIB vs MTZ · P/E 21, rev $9.89B vs P/E 63, rev $8.20B
Biogen Inc (BIIB) versus MasTec Inc (MTZ) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ.
MasTec Inc (MTZ) is a engineering & construction company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported MTZ revenue for 2026-06-30 was $8.20B. Net income was $191.0M. MTZ currently screens at market cap $28.61B and trailing P/E 63.3.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. MTZ currently screens at market cap $28.61B and trailing P/E 63.3.
Not investment advice. Open the BIIB and MTZ stock pages for the full models.
Not investment advice.